BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:BTG
Previous Symbol
CUSIPN/A
Phone+44-20-75750000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees1,631
Outstanding SharesN/A
Market Cap£0.00
OptionableOptionable
BTG (LON:BTG) Frequently Asked Questions
What is BTG's stock symbol?
BTG trades on the London Stock Exchange (LON) under the ticker symbol "BTG."
How were BTG's earnings last quarter?
BTG plc (LON:BTG) issued its earnings results on Tuesday, May, 15th. The company reported $32.90 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $29.80 by $3.10. View BTG's Earnings History.
What price target have analysts set for BTG?
7 brokerages have issued 1 year price targets for BTG's stock. Their predictions range from GBX 490 to GBX 900. On average, they expect BTG's share price to reach GBX 704.17 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for BTG.
What is the consensus analysts' recommendation for BTG?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BTG in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for BTG.
Has BTG been receiving favorable news coverage?
News articles about BTG stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BTG earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of BTG's key competitors?
Some companies that are related to BTG include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are BTG's key executives?
BTG's management team includes the folowing people:
- Dr. Louise Makin MA, Ph.D.(Cantab), MBA, DBE, CEO & Exec. Director (Age 57)
- Mr. Duncan Kennedy A.C.A., B.Sc., CFO & Director
- Dr. Peter Stratford, Chief Technical Officer & Head of Innovation (Age 51)
- Mr. Andy Burrows, VP of Corp. & Investor Relations
- Dr. Paul Mussenden, Gen. Counsel, Head of PnuemRx, Head of Strategic Affairs & Company Sec.
How do I buy shares of BTG?
Shares of BTG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is BTG's stock price today?
One share of BTG stock can currently be purchased for approximately GBX 615.
What is BTG's official website?
How can I contact BTG?
BTG's mailing address is 5 Fleet Place, LONDON, EC4M 7RD, United Kingdom. The company can be reached via phone at +44-20-75750000.
MarketBeat Community Rating for BTG (LON BTG)
MarketBeat's community ratings are surveys of what our community members think about BTG and other stocks. Vote "Outperform" if you believe BTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTG will underperform the S&P 500 over the long term. You may vote once every thirty days.
